Figure 4 from Determinants and Effectiveness of Extending the Duration of Adjuvant Hormone Therapy beyond 5 Years in Patients with Breast Cancer

<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar pe...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yazar: Erwei Zeng (14958443) (author)
Diğer Yazarlar: Wei He (14958446) (author), Arvid Sjölander (14958449) (author), Jenny Bergqvist (14958452) (author), Kamila Czene (14958455) (author)
Baskı/Yayın Bilgisi: 2025
Konular:
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
Diğer Bilgiler
Özet:<p>Disease-free survival and overall survival in patients who extended therapy and those who did not. <b>A</b> and <b>B,</b> Disease-free survival (<b>A</b>) and overall survival (<b>B</b>). Note: HR was adjusted for age at diagnosis, calendar period of cancer diagnosis, tumor size, lymph node status, tumor grade, progesterone receptor status, chemotherapy, radiotherapy, Charlson Comorbidity Index at extension, education, and income at diagnosis.</p>